foxo4 dri human trial senolytic The disordered p53 transactivation domain is the target of and the compound FOXO4-DRI FOXO4-DRI 10mg vial - Description
FOXO4 DRI 10mg vial Description RCpeptides Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry FOXO4 DRI Vial 10mg Stemcode Peptides Emerging strategies in senotherapeutics: from broad spectrum senolysis to precision reprogramming npj Aging
Pay in 4 interest-free payments of $6.47 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12



